The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5470
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis ; day:10 ; month:3 ; year:2018 ; pages:1-5
Genes and immunity ; (10.3.2018), 1-5
- Urheber
-
Watts, Laura
- Beteiligte Personen und Organisationen
-
Karaderi, Tugce
Roberts, Amity
Appleton, Louise
Wordsworth, Tom
Cohen, Carla
Wordsworth, Paul
Vecellio, Matteo
SpringerLink (Online service)
- DOI
-
10.1038/s41435-018-0017-0
- URN
-
urn:nbn:de:1111-2018051617003
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Watts, Laura
- Karaderi, Tugce
- Roberts, Amity
- Appleton, Louise
- Wordsworth, Tom
- Cohen, Carla
- Wordsworth, Paul
- Vecellio, Matteo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Production of tumour necrosis factor during murine cutaneous leishmaniasis
Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
Exogenous tumour necrosis factor α induces suppression of autoimmune arthritis
Commercially Available Antibodies to Human Tumour Necrosis Factor-α Tested for Cross-Reactivity with Ovine and Bovine Tumour Necrosis Factor-α using Flow Cytometric Assays
Natural Inhibitors of Tumour Necrosis Factor-α Production, Secretion and Function
Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Dominant negative biologics normalise the tumour necrosis factor (TNF-α) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Production of tumour necrosis factor during murine cutaneous leishmaniasis
Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
Exogenous tumour necrosis factor α induces suppression of autoimmune arthritis
Commercially Available Antibodies to Human Tumour Necrosis Factor-α Tested for Cross-Reactivity with Ovine and Bovine Tumour Necrosis Factor-α using Flow Cytometric Assays
Natural Inhibitors of Tumour Necrosis Factor-α Production, Secretion and Function
Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Dominant negative biologics normalise the tumour necrosis factor (TNF-α) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Production of tumour necrosis factor during murine cutaneous leishmaniasis
Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
Exogenous tumour necrosis factor α induces suppression of autoimmune arthritis
Commercially Available Antibodies to Human Tumour Necrosis Factor-α Tested for Cross-Reactivity with Ovine and Bovine Tumour Necrosis Factor-α using Flow Cytometric Assays
Natural Inhibitors of Tumour Necrosis Factor-α Production, Secretion and Function
Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Dominant negative biologics normalise the tumour necrosis factor (TNF-α) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination